Trial Profile
Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 30 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 30 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Nov 2012 Planned end date changed from 1 Jul 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.